The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. - Strijbis EM; Repovic P; Mostert J; Bowen JD; Uitdehaag BM; Cutter G; Koch MW (Multiple sclerosis (Houndmills, Basingstoke, England), 2022)